Patents by Inventor Klaus Jensen

Klaus Jensen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11993762
    Abstract: The invention relates to compositions comprising and uses of polypeptides having alpha-mannan degrading activity. The present invention relates to polypeptides having alpha-mannan degrading activity, and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
    Type: Grant
    Filed: October 2, 2019
    Date of Patent: May 28, 2024
    Assignee: Novozymes A/S
    Inventors: Jesper Salomon, Klaus Gori, Lorena González Palmén, Kenneth Jensen, Nikolaj Spodsberg, Mary Ann Stringer, Kristian Bertel Roemer M. Krogh, Morten Gjermansen
  • Publication number: 20220160870
    Abstract: The invention relates to the field of immunotherapy and vaccine treatment of diseased cells via enhancing the immune response to the diseased cells. In the context of the present invention this is done by engineering neo-antigens in cells via oligonucleotide mediated production of aberrant RNA transcripts which, when transcribed in the cell, result in the generation or increased expression of aberrant polypeptides. Extracellular display of these polypeptides, of peptide fragments derived provides antigen epitopes (neoantigen) for detection by the immune system.
    Type: Application
    Filed: August 28, 2019
    Publication date: May 26, 2022
    Inventors: Troels Koch, Kamille Dumong Erichsen, Mads Jensen, Jonas Vikesaa, Lars Joenson, Klaus Jensen, Gianluigi Lichinchi
  • Patent number: 8889142
    Abstract: The present invention is related to antigen from Chlamydia trachomatis which are recognized by specific antibodies from individuals infected with Chlamydia or which can induce T cells from the same individuals to secrete gamma-interferon. The T cell reactive antigens are present in a whole-cell lysate and have apparent molecular weights of 5-12, 16-20, 25-35 and 58-74 kDa as determined by SDS-PAGE. The antigens of the invention are believed to be useful in vaccines but also as diagnostic compositions.
    Type: Grant
    Filed: October 11, 2005
    Date of Patent: November 18, 2014
    Assignee: Statens Serum Institut
    Inventors: Michael Theisen, Anja Olsen, Robert Leah, Frank Follmann, Klaus Jensen, Peter Andersen
  • Publication number: 20140107197
    Abstract: A pharmaceutical composition comprising a docusate; an osmotic laxative; and a benzoate.
    Type: Application
    Filed: December 20, 2013
    Publication date: April 17, 2014
    Applicant: Ferring International Center S.A.
    Inventors: Klaus Jensen, Soren Halskov, Henning Lund
  • Patent number: 8637570
    Abstract: A pharmaceutical composition comprising a docusate; an osmotic laxative; and a benzoate.
    Type: Grant
    Filed: December 5, 2008
    Date of Patent: January 28, 2014
    Assignee: Ferring International Center S.A.
    Inventors: Klaus Jensen, Soren Halskov, Henning Lund
  • Publication number: 20090304722
    Abstract: The present invention is related to antigens from Chlamydia trachomatis which are recognized by specific antibodies from individuals infected with Chlamydia or which can induce T cells from the same individuals to secrete gamma-interferon. The T cell reactive antigens are present in a whole-cell lysate and have apparent molecular weights of 5-12, 16-20, 25-35 and 58-74 kDa as determined by SDS-PAGE. The antigens of the invention are useful in vaccines but also as diagnostic compositions.
    Type: Application
    Filed: October 11, 2005
    Publication date: December 10, 2009
    Inventors: Michael Theisen, Anja Olsen, Robert Leah, Frank Follmann, Klaus Jensen, Peter Andersen
  • Publication number: 20070043075
    Abstract: This invention relates to novel (1R,2R,3S,5S)-2-methoxymethyl-3-(3,4-dichlorophenyl)-8-azabicyclo[3.2.1]octane tartrate salts, such as L-tartrate monohydrates and anhydrates. The salts are useful as monoamine neurotransmitter re-uptake inhibitors. In other aspects the invention relates to the use of these salts in a method for therapy and to pharmaceutical compositions comprising the salts of the invention.
    Type: Application
    Filed: July 29, 2004
    Publication date: February 22, 2007
    Inventors: Brian Frostrup, Frank Watjen, Klaus Jensen
  • Publication number: 20060281758
    Abstract: A compound 4-((1R,3S)-6-Chloro-3-phenylindan-1-yl)-2,2-dimethylpiperazine and salts thereof, pharmaceutical compositions comprising the compound and salts, and medical use thereof, including for treatment of schizophrenia and other psychotic disorders.
    Type: Application
    Filed: August 18, 2004
    Publication date: December 14, 2006
    Inventors: Benny Bang-Andersen, Klaus Bogeso, Henrik Svane, Lars Lyngso, Allan Dahl, Mark Howells, Klaus Jensen, Tomas Mow